Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of subcutaneous daclizumab in active relapsing multiple sclerosis on interferon-beta
2005-001567-55Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Jul 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Daclizumab + interferon-beta with Placebo + interferon-beta (2 arms). Primary endpoint: Number of new or enlarged gadolinium contrast-enhancing lesions on brain MRI. Started Jul 2005; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2005-001567-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001567-55.